*6.2.5. Anticoagulants in the treatment for thrombosis*

Thrombosis is treated by selectively inhibiting the major procoagulant proteins. Major drug targets for the treatment of thrombosis include vitamin K agonists, FXa, FIXa, Thrombin and platelet inhibitors. Current oral anticoagulants approved by FDA are rivaroxaban, Apixaban, dabigatran and endoxaban. Revaroxaban and Apixaban inhibit FXa, whereas dabigatran and endoxaban inhibit thrombin. Several other procoagulant inhibitors such as RNA aptamers are under investigation [123].
